Nvidia, Lilly Team Up For $1B Drug AI Lab
Synopsis
The two companies will invest the funds over five years to build a new joint research lab in the San Francisco Bay area.
Nvidia Corp. (NVDA) and Eli Lilly (LLY) announced on Monday that the two companies will jointly invest $1 billion over five years to build a new joint research lab in the San Francisco Bay area.
The co-innovation lab will leverage Nvidia’s new Vera Rubin chips and be built on the company’s BioNeMo platform, while leveraging Eli Lilly’s pharmaceutical expertise to accelerate medicine development, the companies said.
The lab will expand on the U.S. pharma giant’s previously announced AI supercomputer and intends to use Nvidia’s next-generation architectures.
Shares of NVDA were down 0.39% at the time of writing, while shares of LLY were up 0.89% at the same time.
Get updates to this developing story directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.